BRAF and melanoma: The use of RAF inhibitors such as vemurafenib or sorafenib in BRAF-wild-type cancers has been shown to lead to “paradoxical” activation of ERK in cutaneous squamous cell carcinoma, lung cancer or melanoma, likely due to a direct effect of the drug on RAF dimerization2, 4, 5.